
Allogene Therapeutics, Inc. – NASDAQ:ALLO
Allogene Therapeutics stock price today
Allogene Therapeutics stock price monthly change
Allogene Therapeutics stock price quarterly change
Allogene Therapeutics stock price yearly change
Allogene Therapeutics key metrics
Market Cap | 392.08M |
Enterprise value | 703.51M |
P/E | -2.09 |
EV/Sales | 3589.34 |
EV/EBITDA | -3.13 |
Price/Sales | 3419.86 |
Price/Book | 1.00 |
PEG ratio | 0.09 |
EPS | -1.79 |
Revenue | 130K |
EBITDA | -270.67M |
Income | -290.08M |
Revenue Q/Q | -57.69% |
Revenue Y/Y | -44.44% |
Profit margin | -121318.88% |
Oper. margin | -121977.04% |
Gross margin | 0% |
EBIT margin | -121977.04% |
EBITDA margin | -208214.62% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAllogene Therapeutics stock price history
Allogene Therapeutics stock forecast
Allogene Therapeutics financial statements
Jun 2023 | 44K | -77.98M | -177247.73% |
---|---|---|---|
Sep 2023 | 43K | -61.31M | -142593.02% |
Dec 2023 | 21K | -85.77M | -408466.67% |
Mar 2024 | 22K | -65M | -295454.55% |
Mar 2024 | 22K | -65M | -295454.55% |
---|---|---|---|
Sep 2025 | 11.5K | -63.77M | -554600.68% |
Oct 2025 | 10.63K | -64.53M | -606801.27% |
Dec 2025 | 10.63K | -65.38M | -614736.11% |
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 770971000 | 148.06M | 19.21% |
---|---|---|---|
Sep 2023 | 712326000 | 129.22M | 18.14% |
Dec 2023 | 642837000 | 130.60M | 20.32% |
Mar 2024 | 586350000 | 124.98M | 21.32% |
Jun 2023 | -61.85M | 17.16M | 89.52M |
---|---|---|---|
Sep 2023 | -55.53M | -34.26M | 4.28M |
Dec 2023 | -53.70M | 67.46M | 155K |
Mar 2024 | -55.89M | 22.13M | 1.65M |
Allogene Therapeutics alternative data
Sep 2023 | 359 |
---|---|
Oct 2023 | 359 |
Nov 2023 | 359 |
Dec 2023 | 359 |
Jan 2024 | 359 |
Feb 2024 | 359 |
Apr 2024 | 232 |
May 2024 | 232 |
Jun 2024 | 232 |
Jul 2024 | 232 |
Allogene Therapeutics other data
Period | Buy | Sel |
---|---|---|
Jan 2024 | 190 | 0 |
May 2024 | 1724137 | 11200 |
Jun 2024 | 0 | 18641 |
Dec 2024 | 0 | 18357 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Sale | MESSEMER DEBORAH M. director | Common Stock | 9,136 | $2.18 | $19,916 | ||
Sale | HUMER FRANZ B director | Common Stock | 9,221 | $2.16 | $19,917 | ||
Sale | MESSEMER DEBORAH M. director | Common Stock | 18,641 | $2.28 | $42,483 | ||
Sale | HUMER FRANZ B director | Common Stock | 11,200 | $2.34 | $26,186 | ||
Purchase | BELLDEGRUN ARIE director | Common Stock | 1,724,137 | $2.9 | $4,999,997 | ||
Purchase | PARKER GEOFFREY M. officer: CHIEF FI.. | Common Stock | 190 | $3.6 | $683 | ||
Sale | MESSEMER DEBORAH M. director | Common Stock | 18,640 | $2.7 | $50,309 | ||
Sale | MAYO STEPHEN director | Common Stock | 10,000 | $4.29 | $42,860 | ||
Sale | BHAVNAGRI VEER officer: General .. | Common Stock | 3,000 | $6.85 | $20,550 | ||
Sale | BHAVNAGRI VEER officer: General .. | Common Stock | 3,000 | $7.04 | $21,120 |
Patent |
---|
Application FASL EXPRESSION AND FASR GENE KNOCKOUT TO PROTECT THERAPEUTIC CELLS FROM ALLOGENEIC REJECTION AND ACTIVATION-INDUCED CELL DEATH Filling date: 4 Mar 2022 Issue date: 8 Sep 2022 |
Application KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS Filling date: 28 Jan 2022 Issue date: 11 Aug 2022 |
Application Filling date: 3 Feb 2022 Issue date: 4 Aug 2022 |
Application Filling date: 8 Apr 2022 Issue date: 28 Jul 2022 |
Application Filling date: 21 Dec 2021 Issue date: 21 Jul 2022 |
Application Filling date: 14 Dec 2021 Issue date: 16 Jun 2022 |
Grant Filling date: 31 Oct 2018 Issue date: 10 May 2022 |
Application Filling date: 26 Jul 2021 Issue date: 3 Feb 2022 |
Application Filling date: 21 Jul 2021 Issue date: 27 Jan 2022 |
Application Filling date: 24 Feb 2021 Issue date: 26 Aug 2021 |
Quarter | Transcript |
---|---|
Q1 2024 13 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 14 Mar 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 2 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 2 Aug 2023 | Q2 2023 Earnings Call Transcript |
Insider | Compensation |
---|---|
Dr. David D. Chang M.D., Ph.D. (1960) Co-Founder, Pres, Chief Executive Officer & Director | $1,260,000 |
Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D. (1949) Co-Founder & Executive Chairman | $845,190 |
Dr. Rafael G. Amado (1964) Chief Medical Officer and Executive Vice President of R&D | $840,000 |
Dr. Eric Thomas Schmidt Ph.D. (1970) Chief Financial Officer | $660,000 |
Dr. Alison Moore Ph.D. (1967) Chief Technical Officer | $660,000 |
Mr. Veer Bhavnagri (1983) Gen. Counsel & Compliance Officer | $646,880 |
Mr. Joshua A. Kazam (1977) Co-Founder & Director | $390,000 |
Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment
Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade)
Cellectis: Poised To Start Answering Questions In 2025
Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products
Cellectis: 2 Data Readouts Of Blood Cancer Studies By End Of 2024
Showcasing Seeking Alpha's March 2024 New Analysts
CytoMed Therapeutics: An Innovative Immunology Biotech Company To Watch
Allogene: I Am Less Sanguine About Allogeneic CAR-T's Prospects Than Before
SpringWorks Therapeutics: FDA Decision Date Ahead
-
What's the price of Allogene Therapeutics stock today?
One share of Allogene Therapeutics stock can currently be purchased for approximately $1.07.
-
When is Allogene Therapeutics's next earnings date?
Unfortunately, Allogene Therapeutics's (ALLO) next earnings date is currently unknown.
-
Does Allogene Therapeutics pay dividends?
No, Allogene Therapeutics does not pay dividends.
-
How much money does Allogene Therapeutics make?
Allogene Therapeutics has a market capitalization of 392.08M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 60.91% to 95K US dollars.
-
What is Allogene Therapeutics's stock symbol?
Allogene Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "ALLO".
-
What is Allogene Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Allogene Therapeutics?
Shares of Allogene Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Allogene Therapeutics's key executives?
Allogene Therapeutics's management team includes the following people:
- Dr. David D. Chang M.D., Ph.D. Co-Founder, Pres, Chief Executive Officer & Director(age: 65, pay: $1,260,000)
- Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D. Co-Founder & Executive Chairman(age: 76, pay: $845,190)
- Dr. Rafael G. Amado Chief Medical Officer and Executive Vice President of R&D(age: 61, pay: $840,000)
- Dr. Eric Thomas Schmidt Ph.D. Chief Financial Officer(age: 55, pay: $660,000)
- Dr. Alison Moore Ph.D. Chief Technical Officer(age: 58, pay: $660,000)
- Mr. Veer Bhavnagri Gen. Counsel & Compliance Officer(age: 42, pay: $646,880)
- Mr. Joshua A. Kazam Co-Founder & Director(age: 48, pay: $390,000)
-
Is Allogene Therapeutics founder-led company?
Yes, Allogene Therapeutics is a company led by its founders Dr. David D. Chang M.D., Ph.D., Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D. and Mr. Joshua A. Kazam.
-
How many employees does Allogene Therapeutics have?
As Jul 2024, Allogene Therapeutics employs 232 workers.
-
When Allogene Therapeutics went public?
Allogene Therapeutics, Inc. is publicly traded company for more then 6 years since IPO on 11 Oct 2018.
-
What is Allogene Therapeutics's official website?
The official website for Allogene Therapeutics is allogene.com.
-
Where are Allogene Therapeutics's headquarters?
Allogene Therapeutics is headquartered at 210 East Grand Avenue, South San Francisco, CA.
-
How can i contact Allogene Therapeutics?
Allogene Therapeutics's mailing address is 210 East Grand Avenue, South San Francisco, CA and company can be reached via phone at +65 04572700.
Allogene Therapeutics company profile:

Allogene Therapeutics, Inc.
allogene.comNASDAQ
232
Biotechnology
Healthcare
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
South San Francisco, CA 94080
CIK: 0001737287
ISIN: US0197701065
CUSIP: 019770106